Robert Bosch Venture Capital, the corporate venture capital company of the Bosch Group, has completed an investment in Variantyx Inc.
Variantyx and Robert-Bosch Hospital join forces to improve personalised oncology treatment with plans to incorporate the Variantyx solution into the oncology treatment process. Variantyx provides clinicians with advanced diagnostics and personalised treatment recommendations for oncology patients’ based on their unique genetic makeup.
“For several years the Robert-Bosch Hospital, the Robert Bosch Stiftung, and the Bosch Group have been joining forces to fight cancer,” says Dr Ingo Ramesohl, Managing Director of Robert Bosch Venture Capital. “Variantyx’s solution is outstanding. Together, Variantyx and Bosch are eying to bring new research, diagnostics, and precision medicine to oncology patients and clinicians.”
The Variantyx proprietary platform and comprehensive data analysis enable a better understanding of each patient’s unique genetic composition, providing industry leading diagnoses and personalisued treatment recommendations. Variantyx’s tests delve deep into the genetics of an individual, providing insights and analytics that no other diagnostic laboratory can deliver today. Variantyx’s oncology solutions identify the unique genetic alterations in a patient’s tumor. Profiling these alterations helps predict the patient’s response to various therapies, enabling clinicians to provide the most effective personalised care for their patients.
According to a recent Markets And Markets report, the global genomic diagnostics market size was valued at USD22.7 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 19 per cent between 2021 and 2025.
“Partnering with RBK enables an entirely new approach to cancer treatment by analysing the specifics of each individual patient and personalising care to optimise their healthcare treatment,” says Haim Neerman, co-Founder & Chief Executive Officer at Variantyx. “This opens the door for other areas of medical intervention to take a more innovative and individualised approach to treatment.”
The Robert Bosch Center for Tumor Diseases (RBCT) is part of the Robert Bosch Medical Research (RBMF) and focuses on improving the treatment of cancer patients. Patients at the Robert-Bosch Hospital are advised and treated in line with the latest research results.”
Variantyx’s solution can very well complement the existing and established activities in tumour-research to bring new research quickly to the patient. We are pleased to partner with Variantyx, utilising their unique proprietary software to analyse data more precisely to create a more insightful approach to cancer therapy,” says Helia Schönthaler, COO of Robert Bosch Medical Research.
